In our daily work in a company or freelance setting, we interact with other relevant functions, typically biostatistical, medical, programming, and data management colleagues, so that we can deliver wellrounded deliverables that take account of multiple perspectives. If we take a higher-level strategic view for the developing regulatory public disclosure (RPD) arena, then we should be talking to professionals outside of our usual networks to ensure we understand and take account of broader perspectives. I engaged with Cathal Gallagher of EMA’s Technical Anonymisation Group and asked him the kinds of questions that you as medical writers might, and hope to have contextualised his RPD perspectives to our work in writing clinical documents fit for public disclosure.
Editor-in-Chief
Co-Editors
Managing Editor
Victoria White
Associate Editors
Section Editors
Biotechnology
Digital Communication
EMWA News
Gained in Translation
Getting Your Foot in the Door
Good Writing Practice
In the Bookstores
Manuscript Writing
Medical Communications/Writing for Patients
Medical Devices
My First Medical Writing
News from the EMA
Out on Our Own
Pharmacovigilance
Regulatory Matters
Regulatory Public Disclosure
Teaching Medical Writing
The Crofter: Sustainable Communications
Veterinary Writing
Editors Emeritus
Lay out Designer
Chris Monk